Posted by Michael Wonder on 08 Mar 2021
SMC - March 2021 decisions
8 March 2021 - Medicines which can be used to treat a rare genetic disease in children and some cancer tumours with a genetic abnormality have today been accepted by the SMC for use by NHSScotland.
Onasemnogene abeparvovec (Zolgensma) is a gene therapy for the treatment of spinal muscular atrophy. It is the first gene therapy SMC has accepted for use by NHSScotland.
